Literature DB >> 3119941

Adrenoleukodystrophy: biochemical procedures in diagnosis, prevention and treatment.

P A Watkins1, S Naidu, H W Moser.   

Abstract

The childhood form of adrenoleukodystrophy is an X-linked recessive disorder which is characterized biochemically by elevated concentrations of saturated very long chain fatty acids in tissues and plasma and impaired very long chain fatty acid oxidation in fibroblasts and leukocytes from adrenoleukodystrophy patients. The most consistently observed increase is that in hexacosanoic acid (C26:0); thus, measurement of plasma C26:0 concentration by gas-liquid chromatography provides a rapid, sensitive method of diagnosis. Prenatal diagnosis of adrenoleukodystrophy can be made by measurement of C26:0 concentrations in amniocytes and chorionic villus cells. Heterozygote (carrier) detection has also been accomplished by biochemical measurement of C26:0 in plasma and skin fibroblasts. In a study of over 200 obligate heterozygotes, greater than 90% showed abnormal concentrations of C26:0. Hybridization studies using the cloned DNA fragment St14 detects polymorphisms in the distal end of the long arm of the X chromosome (Xq27-28) and six informative kindreds have shown co-segregation of adrenoleukodystrophy and the St14 marker through 65 meioses. Thus, such studies can supplement very long chain fatty acid concentrations in heterozygote detection. Therapeutic interventions for adrenoleukodystrophy, such as dietary restriction of very long chain fatty acids, administration of clofibrate or carnitine, immunosuppression and adrenal hormone replacement, have not been successful. Recently, a modification of the very long chain fatty acid-restricted diet has been employed in which this diet is supplemented with synthetic glycerol trioleate. The rationale for this diet is that decreased very long chain fatty acid synthesis by fibroblasts from patients with adrenoleukodystrophy was observed when oleic acid was added to the culture medium.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3119941     DOI: 10.1007/bf01812846

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  18 in total

1.  Peroxisomal disorders.

Authors:  H W Moser
Journal:  J Pediatr       Date:  1986-01       Impact factor: 4.406

2.  Heredopathia atactica polyneuritiformis phytanic-acid storage disease, Refsum's disease:" a biochemically well-defined disease with a specific dietary treatment.

Authors:  S Refsum
Journal:  Arch Neurol       Date:  1981-10

3.  Bone marrow transplant in adrenoleukodystrophy.

Authors:  H W Moser; P J Tutschka; F R Brown; A E Moser; A M Yeager; I Singh; S A Mark; A A Kumar; J M McDonnell; C L White
Journal:  Neurology       Date:  1984-11       Impact factor: 9.910

4.  Adrenoleukodystrophy: impaired oxidation of very long chain fatty acids in white blood cells, cultured skin fibroblasts, and amniocytes.

Authors:  I Singh; A E Moser; H W Moser; Y Kishimoto
Journal:  Pediatr Res       Date:  1984-03       Impact factor: 3.756

5.  Identification of the inflammatory cells in the central nervous system of patients with adrenoleukodystrophy.

Authors:  D E Griffin; H W Moser; Q Mendoza; T R Moench; S O'Toole; A B Moser
Journal:  Ann Neurol       Date:  1985-12       Impact factor: 10.422

6.  Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy.

Authors:  I Singh; A E Moser; S Goldfischer; H W Moser
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

7.  Linkage of adrenoleukodystrophy to a polymorphic DNA probe.

Authors:  P R Aubourg; G H Sack; D A Meyers; J J Lease; H W Moser
Journal:  Ann Neurol       Date:  1987-04       Impact factor: 10.422

8.  Adrenoleukodystrophy: evidence for X linkage, inactivation, and selection favoring the mutant allele in heterozygous cells.

Authors:  B R Migeon; H W Moser; A B Moser; J Axelman; D Sillence; R A Norum
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

9.  Adrenoleukodystrophy: survey of 303 cases: biochemistry, diagnosis, and therapy.

Authors:  H W Moser; A E Moser; I Singh; B P O'Neill
Journal:  Ann Neurol       Date:  1984-12       Impact factor: 10.422

10.  Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids.

Authors:  H W Moser; A B Moser; K K Frayer; W Chen; J D Schulman; B P O'Neill; Y Kishimoto
Journal:  Neurology       Date:  1981-10       Impact factor: 9.910

View more
  5 in total

Review 1.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

Authors:  Walter L Miller; Richard J Auchus
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

2.  X-linked adrenoleukodystrophy presenting as Addison's disease.

Authors:  Bernhard Kaspar Morell; Jens Teichler; Kemal Budak; Jörg Vollenweider; Vojtech Pavlicek
Journal:  BMJ Case Rep       Date:  2010-05-13

3.  Characterization of X-linked adrenoleukodystrophy in different biological specimens from ten Portuguese families.

Authors:  P Jorge; D Quelhas; A Nogueira
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

Review 4.  Molecular Biomarkers in Multiple Sclerosis and Its Related Disorders: A Critical Review.

Authors:  Maryam Gul; Amirhossein Azari Jafari; Muffaqam Shah; Seyyedmohammadsadeq Mirmoeeni; Safee Ullah Haider; Sadia Moinuddin; Ammar Chaudhry
Journal:  Int J Mol Sci       Date:  2020-08-21       Impact factor: 5.923

Review 5.  Brain Lipotoxicity of Phytanic Acid and Very Long-chain Fatty Acids. Harmful Cellular/Mitochondrial Activities in Refsum Disease and X-Linked Adrenoleukodystrophy.

Authors:  Peter Schönfeld; Georg Reiser
Journal:  Aging Dis       Date:  2016-03-15       Impact factor: 6.745

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.